Shall we include US findings in CASPAR criteria? ⚡️ Adding US tenosynovitis and/or enthesitis - improves Specificity 91% vs. 68% -while maintaining sensitivity 92% vs. 96% #EULAR2022 @RheumNow POS0315 https://t.co/kuxPpVEQng

Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by week 2. Higher baseline pain, lower fatigue, lower TJC + predictors, NSAID use - predictor @RheumNow #EULAR2022 POS1070 https://t.co/4aNz9IQySj

The potential for patients to benefit from digital health technologies in rheumatology is multifaceted, upside might be enormous. There's so much space for us all, but there are factors in many domains where it can all go wrong. We need to raise standards. #EULAR2022 @RheumNow https://t.co/TozfK1Qs16

High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psoriatic arthritis. Analysis of RCT @eular_org @RheumNow #POS0005 Good proof of concept of TYK2 efficacy https://t.co/yyH5niUEEU

Therkildsen et al Ocular manifestations GCA in Denmark. Quite low proportion at 7%. Most occur around time diagnosis, with 1/3 pre-diagnosis. Aspirin not assoc reduced risk. @RheumNow #EULAR2022 POS0791 https://t.co/YgailfJ6fI

New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bDMARD-IR (ASAS40 45% vs 18% and the onset of effect seen by week 4), no new safety risks identified in the SELECT-AXIS 2 study by Van de Heijde et al #EULAR2022 @RheumNow POS0306 https://t.co/LCQBf38GWe

CorEvitas PsA Registry (1000+ pts) Analysis of biologics prescription according to disease domains No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL Overall first line TNFi 40% > IL-17i 14% POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug

Everything's better with MTX Controlled RA on b/tsDMARDs: can we taper MTX? maintaining remission pooled OR 0.81 (0.68-0.97) Unless I'm reading it wrong: it's true many will be fine, but keeping MTX adds benefit (even in short term, before ADAb) POS0286 #EULAR2022 @RheumNow https://t.co/ZlwXHgACWd

SELECT-AXIS 1 trial of upadacitinib in active #AS with an inadequate resp to prior biologic - pivotal phase 2/3 RCT of 420 AS pts (Dz dur 7.7 yrs; 83% B27+) showed better ASAS40 at wk 14 w/ UPA vs PBO (45% vs 18%; P<0.0001) #EULAR2022 POS0306 https://t.co/6ZBEvjRjqc https://t.co/GL0vlB34mE

• https://bit.ly/3zdWc6A

Cantoni et al. Maladaptive trained immunity in GCA. Aberrant activation of trained immunity programs in myelomonocytic cells leads to sustained and enhanced inflammatory activation and increased expression inflammatory cytokines (esp IL6) @RheumNow #EULAR2022 POS0492 https://t.co/A8t9gV1O3d

Charles-Schoeman et al. ORAL Surveillance, post-hoc analysis of risk factor combinations. 65+ ever smokers appear at particular risk @RheumNow #EULAR2022 POS0674 https://t.co/UyTOITBTX9

If rheumatoid arthritis comes and goes before a rheumatologist lays their hands on it, is it really RA? We're born skeptical on this. Ronald van Vollenhoven poses questions on what it means for studying drug-free remission in established RA disease #EULAR2022 @RheumNow https://t.co/9GJoqYtVBP

Dr Aggarwal @docrota et al. Abatacept RCT in IIM. Overall negative trial. Pre-specified and post-hoc analyses suggest some benefit in PM/ANM but not in DM @RheumNow #EULAR2022 POS0839 https://t.co/uttMLKy9fW

Palmowski et al. Glucocorticoids and bone density in GCA/PMR/other vasculitis from Rh-GIOP. Weird one, no increase in osteoporosis, no association with current or cumulative steroid dose and osteoporosis. Low BMI, vert #, PPIs were assoc osteoporosis. @RheumNow #EULAR2022 POS1139 https://t.co/n3d6YArXmU

The two forms of Axial PsA - classical (Axial SpA like) and alternative. Plenary session today #EULAR2022 by Prof. Philip Helliwell. I will be discussing this further in my vlog @RheumNow https://t.co/hxAhgMhHlJ